ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

RSLS ReShape Lifesciences Inc

0,2199
-0,0143 (-6,11%)
08 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
ReShape Lifesciences Inc RSLS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
-0,0143 -6,11% 0,2199 06:00:07
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,23 0,218 0,2308 0,225 0,2342
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
20/5/202423:14EDGAR2Form 8-K - Current report
15/5/202422:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
15/5/202422:05GLOBEReShape Lifesciences® Reports First Quarter Ended March 31,..
14/5/202414:31GLOBEReShape Lifesciences® to Announce Financial Results for the..
01/4/202422:05GLOBEReShape Lifesciences® Reports Year Ended December 31, 2023..
28/3/202413:31GLOBEReShape Lifesciences® Receives Notice of Allowance for..
04/3/202414:31GLOBEReShape Lifesciences® Provides Update on 2024 Cost Reduction..
26/2/202422:19EDGAR2Form 8-K - Current report
22/2/202414:31GLOBEReShape Lifesciences® Announces First Surgeries Utilizing..
24/1/202414:31GLOBEReShape Lifesciences® Conducts Bariatric Fellows Training..
18/1/202422:38EDGAR2Form 8-K - Current report
17/1/202400:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/1/202422:14EDGAR2Form PRE 14A - Other preliminary proxy statements
20/12/202314:31GLOBEReShape Lifesciences® Engages Maxim Group LLC To Identify..
12/12/202322:05GLOBEReShape Lifesciences® Receives FDA PMA Supplement Approval..
29/11/202322:05EDGAR2Form 8-K - Current report
21/11/202314:06GLOBEReShape Lifesciences® Enters into Warrant Exercise..
08/11/202322:05GLOBEReShape Lifesciences® Reports Third Quarter Ended September..
06/11/202314:31GLOBEReShape Lifesciences® to Announce Financial Results for the..
13/10/202322:42EDGAR2Form 8-K - Current report
05/10/202322:05EDGAR2Form 8-K - Current report
03/10/202315:23EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
29/9/202318:30GLOBEReShape Lifesciences® Announces Pricing of $3.0 Million..
27/9/202323:30EDGAR2Form S-1/A - General form for registration of securities..
22/9/202322:02EDGAR2Form 8-K - Current report
22/9/202314:31GLOBEReShape Lifesciences® Announces Participation in the LD..
21/9/202314:31GLOBEReShape Lifesciences® Signs Exclusive License Agreement With..
19/9/202314:31GLOBEReShape Lifesciences® Significantly Strengthens Patent..
14/9/202314:31GLOBEReShape Lifesciences® Receives NIH SBIR Grant to Further..
25/8/202322:41EDGAR2Form S-1 - General form for registration of securities under..
07/8/202323:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:54EDGAR2Form 8-K - Current report
07/8/202322:05GLOBEReShape Lifesciences® Reports Second Quarter Ended June 30,..
03/8/202322:05GLOBEReShape Lifesciences® to Announce Financial Results for the..
29/6/202314:31GLOBEReShape Lifesciences® Signs Preferred Partner Agreement With..
28/6/202314:31GLOBEReShape Lifesciences® Presents Data on its Proprietary..
26/6/202322:05GLOBEReShape Lifesciences® Submits FDA PMA Supplement Application..
23/6/202314:35GLOBELife Science Investor Forum: Presentations Now Available for..
20/6/202316:58GLOBELife Science Investor Forum Agenda Announced for June 22nd
14/6/202314:31GLOBEReShape Lifesciences® to Participate in Investor and..

Dernières Valeurs Consultées

Delayed Upgrade Clock